tiprankstipranks
Trending News
More News >
NanoCarrier Co., Ltd. (JP:4571)
:4571

NanoCarrier Co., Ltd. (4571) AI Stock Analysis

Compare
1 Followers

Top Page

JP:4571

NanoCarrier Co., Ltd.

(4571)

Select Model
Select Model
Select Model
Underperform 40 (OpenAI - 5.2)
Rating:40Underperform
Price Target:
¥134.00
▲(0.00% Upside)
The score is primarily held down by weak financial performance driven by declining revenue, persistent large losses, and continued cash burn. Technical signals are also soft with the stock below key moving averages and negative MACD, while valuation is constrained by negative earnings and no dividend support.
Positive Factors
High Gross Margin
A high gross margin indicates efficient production and pricing strategies, providing a buffer against operational inefficiencies and supporting potential profitability improvements.
Manageable Leverage
Low leverage enhances financial flexibility, allowing the company to navigate through challenging periods without excessive debt burdens, supporting long-term stability.
Improved Cash Burn Rate
An improved cash burn rate suggests better cost management and operational efficiency, which can extend the company's runway and reduce the need for external financing.
Negative Factors
Declining Revenue
Continued revenue decline limits scale and operating leverage, challenging the company's ability to cover fixed costs and invest in growth, impacting long-term viability.
Persistent Large Losses
Ongoing large losses indicate that expenses significantly exceed revenues, which can erode equity and limit the company's ability to invest in future growth opportunities.
Negative Cash Flow
Negative cash flow suggests the company is not generating sufficient cash from operations to sustain itself, increasing reliance on external funding and posing a risk to long-term sustainability.

NanoCarrier Co., Ltd. (4571) vs. iShares MSCI Japan ETF (EWJ)

NanoCarrier Co., Ltd. Business Overview & Revenue Model

Company DescriptionNANO MRNA Co., Ltd. engages in the research, development, and production of pharmaceuticals using micellar nanoparticles technology. The company develops biopharmaceutical products focused on the medication of cancer and other intractable diseases. It also engages in the research, development, manufacture, and sale of anti-cancer drugs based on micellar nanoparticle technology. The company was founded by Kazunori Kataoka, Teruo Okano, and Ichiro Nakatomi on June 14, 1996 and is headquartered in Tokyo, Japan.
How the Company Makes MoneyNanoCarrier Co., Ltd. generates revenue primarily through the development, licensing, and commercialization of its proprietary drug delivery systems. The company collaborates with pharmaceutical companies to co-develop drugs using its nanotechnology platforms, earning revenues from licensing fees, milestone payments, and royalties on sales of co-developed products. Additionally, NanoCarrier may receive funding from government grants or private investments to support its research and development activities. Strategic partnerships and collaborations with other biotech and pharmaceutical companies also play a significant role in enhancing its market reach and financial performance.

NanoCarrier Co., Ltd. Financial Statement Overview

Summary
NanoCarrier Co., Ltd. is experiencing financial difficulties with declining revenues and substantial operational losses. Despite a strong equity position and conservative debt management, the persistent lack of profitability and negative cash flows raise concerns about its long-term financial sustainability.
Income Statement
NanoCarrier Co., Ltd. has been experiencing declining revenue over the years, with the TTM (Trailing-Twelve-Months) revenue dropping significantly from previous periods. The company has negative profit margins, indicating it is not profitable. Both EBIT and EBITDA margins are deeply negative, reflecting operational challenges.
Balance Sheet
The balance sheet shows a relatively strong equity position, with a low debt-to-equity ratio, indicating conservative leverage. However, the company's equity is decreasing over time. The equity ratio is solid, suggesting a strong reliance on equity financing, which is positive in managing financial risk.
Cash Flow
Cash flow analysis reveals significant challenges, with consistently negative free cash flow indicating cash outflows exceeding inflows. The company has not generated positive operating cash flow recently, which could threaten liquidity if this continues.
BreakdownTTMDec 2024Dec 2023Dec 2022Dec 2021Dec 2020
Income Statement
Total Revenue116.10M108.52M135.51M202.19M264.03M313.26M
Gross Profit84.46M78.17M110.96M159.60M222.74M274.89M
EBITDA-776.70M-832.57M-863.00M-1.25B-2.06B-1.30B
Net Income-879.96M-835.38M-780.00M-1.31B-1.88B-2.84B
Balance Sheet
Total Assets3.93B4.00B5.07B5.78B7.14B7.82B
Cash, Cash Equivalents and Short-Term Investments3.40B3.51B4.28B4.44B5.95B6.40B
Total Debt540.24M540.24M1.11B1.11B1.15B0.00
Total Liabilities1.28B1.26B1.65B1.53B1.57B321.00M
Stockholders Equity2.66B2.74B3.42B4.25B5.57B7.50B
Cash Flow
Free Cash Flow0.000.00-585.08M-1.09B-1.76B-1.25B
Operating Cash Flow0.00-401.62M-585.08M-1.09B-1.75B-1.25B
Investing Cash Flow0.00587.53M793.01M1.21B-244.13M-871.69M
Financing Cash Flow0.00-568.77M3.73M32.20M1.15B-11.46M

NanoCarrier Co., Ltd. Technical Analysis

Technical Analysis Sentiment
Neutral
Last Price134.00
Price Trends
50DMA
148.32
Negative
100DMA
151.06
Negative
200DMA
143.66
Positive
Market Momentum
MACD
-0.77
Negative
RSI
53.32
Neutral
STOCH
84.32
Negative
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For JP:4571, the sentiment is Neutral. The current price of 134 is below the 20-day moving average (MA) of 140.75, below the 50-day MA of 148.32, and below the 200-day MA of 143.66, indicating a neutral trend. The MACD of -0.77 indicates Negative momentum. The RSI at 53.32 is Neutral, neither overbought nor oversold. The STOCH value of 84.32 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for JP:4571.

NanoCarrier Co., Ltd. Peers Comparison

Overall Rating
UnderperformOutperform
Sector (51)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
55
Neutral
¥11.60B36.0683.60%
51
Neutral
$7.86B-0.30-43.30%2.27%22.53%-2.21%
50
Neutral
¥44.44B-18.47-9.04%13.09%
46
Neutral
¥8.47B-6.225.44%-2.17%
45
Neutral
¥8.01B-8.7025.28%39.15%
40
Underperform
¥10.80B-13.65-26.70%172.39%8.27%
39
Underperform
¥5.99B-4.591221.43%30.54%
* Healthcare Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
JP:4571
NanoCarrier Co., Ltd.
146.00
-2.00
-1.35%
JP:2370
MEDINET Co., Ltd.
32.00
-3.00
-8.57%
JP:4583
Chiome Bioscience Inc.
117.00
-162.00
-58.06%
JP:4584
Kidswell Bio Corporation
234.00
129.00
122.86%
JP:4588
Oncolys BioPharma, Inc.
1,519.00
1,002.00
193.81%
JP:4594
BrightPath Biotherapeutics Co.Ltd.
53.00
10.00
23.26%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: Dec 30, 2025